PACT Awarded US Patent for Thermo Shield™ Fire Suppressant Shipping Wrap

PACT, LLC, an innovator of packaging and crating technologies, has been granted a US patent for its Thermo Shield, a paper-based, fire-resistant shipping wrapdesigned to prevent catastrophes caused by battery explosions during transport. Utilizing a revolutionary technology that actively and automatically cools the internal environment of a corrugated container, the paper-based, 100% recyclable protective logistics product prevents damage to the outside shipping container, suppresses fumes or gasses from escaping, and limits external oxygen supply.

Thermo Shield comprises a lightweight pleated material with a non-toxic moisture vapor application that ensures the safety of lithium-ion products in transport. The solution can suppress thermal runaway and propagation at temperatures up to 800°C, and restrict the temperature outside the wrap itself to 60°C.

Importantly considering the push for sustainable packing solutions, the pleated paper is an eco-friendly material that protects the environment even while shielding items from hazardous thermal runaway events, including fires.

The solution’s credentials are a step up from competitors: Thermo Shield is a paper-based wrap solution that exceeds the proposed SAE G27 lithium battery packaging performance standards for safety in shipping.The shipper also is lightweight and reusable, lending to cost efficiency both at initial purchase and during use.

The urgent industry need to mitigate dangerous thermal runaway events makes Thermo Shield a potentially groundbreakingsolution, one capable of drastically limiting the amount of thermal runaway to protect both logistics personnel and valuable cargo.Per the United Parcel Service (UPS), just seven of their customers are responsible for shipping over 40 million lithium-ion batteries per year. Further, the majority of cells or battery packs are produced in Asia, leading to long transit times when shipping to the Western Hemisphere.

Thermo Shield’s one-of-a-kind design allows it to suppress serious thermal runaway incidents, protecting freight transporters and the cargo they’re tasked with delivering,” said Rodger Mort, President of PACT, LLC. “Being recognized with a US patent serves as validation that Thermo Shield™ not only works, but does so in a novel, unique fashion.”

More here.

SourcePact LLC

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version